Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Mechanism of action of the novel SEMA4D inhibitor, pepinemab

The monoclonal antibody, pepinemab, is an inhibitor of SEMA4D, a protein commonly expressed in tumors and the tumor microenvironment. Research indicates that inhibition of SEMA4D could allow immune cells to better attack tumor cells, meaning patients could potentially achieve better responses with immunotherapy. Terrence L. Fisher, Vaccinex Inc., explains the mechanism of action of pepinemab and the rationale behind targeting SEMA4D. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.